Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth "Neurocrine's third quarter commercial results highlight the meaningful impact that INGREZZA and CRENESSITY are having on patients' lives. INGREZZA achieved another record quarter in new patient starts and total prescriptions, further demonstrating continued unmet need within the tardive dyskinesia and Huntington's chorea market. CRENESSITY's strong launch reflects its status as a first-in-class therapy that is changing ...